Benevolent AI (XAMS:BAI) Short-Term Debt : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Benevolent AI Short-Term Debt?

Benevolent AI's Short-Term Debt for the quarter that ended in Dec. 2023 was €0.00 Mil.

Benevolent AI Short-Term Debt Historical Data

The historical data trend for Benevolent AI's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Short-Term Debt Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

Benevolent AI Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial				-	-	-	-	-

Benevolent AI Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Benevolent AI Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (XAMS:BAI) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.